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ABSTRACT: Biomolecules adsorbed on nanoparticles are known to confer a biological
identity to nanoparticles, mediating the interactions with cells and biological barriers.
However, how these molecules are presented on the particle surface in biological milieu
remains unclear. The central aim of this study is to identify key protein recognition motifs
and link them to speciﬁc cell-receptor interactions. Here, we employed an immuno-mapping
technique to quantify epitope presentations of two major proteins in the serum corona, low-
density lipoprotein and immunoglobulin G. Combining with a purpose-built receptor
expression system, we show that both proteins present functional motifs to allow
simultaneous recognition by low-density lipoprotein receptor and Fc-gamma receptor I of
the corona. Our results suggest that the “labeling” of nanoparticles by biomolecular
adsorption processes allows for multiple pathways in biological processes in which they may
be “mistaken” for endogenous objects, such as lipoproteins, and exogenous ones, such as
viral infections.
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When the nanoparticle (NP) surface comes in contactwith a biological milieu, adsorption processes lead toa surface assembly of biomolecules derived from the
environment, which has been termed “biomolecular coro-
na”.1−3 It is now widely acknowledged that suﬃciently long-
lived (“hard corona”) biomolecular motifs presented at the
surface would deﬁne how a NP ﬁrst interacts with and is
recognized by cells,4−11 and such interactions likely deﬁne
many key biological outcomes (e.g., biodistribution, targeting,
and immune responses).12−25 For example, apolipoproteins
and immunoglobulins have been identiﬁed in the biomolecular
corona of various types of NPs.3 Their presence has been
suggested to promote active processes driven by receptors on
the cells of the liver, which leads to liver accumulation of NPs
that have commonly been observed for many types of NPs.26
However, so far, the identities of the proteins that were tightly
bound to an ensemble of NPs have been determined by mass
spectrometry analysis of all the proteins extracted from the
surface of all the NPs,3,27 which provides little information on
how these proteins are organized, and their binding motifs are
presented. The lack of molecular details of corona con-
formation has hindered us from meaningfully determining
“what the cell sees”.28,29 Approaches using immuno-probes for
detection of speciﬁc protein epitopes presented outward on the
NP surface have recently been developed.30,31 These allow us
to seek direct microscopic molecular connections between the
biomolecular corona and speciﬁc receptors.
Here, we present a systematic method to advance such
hypotheses by direct investigation of NP−receptor interactions
in biological milieu. As one example, a protein corona derived
from human serum on 100 nm silica (SiO2) NPs was chosen as
a model. Given the abundance of low-density lipoprotein
(LDL) and immunoglobulin G (IgG) in the corona
characterized by proteomics analysis, their orientation on the
corona was probed by mapping the epitopes of apolipoprotein
B-100 (ApoB-100) for the LDL and Fc region for IgG.
Approximately, 60 ApoB-100 binding sites and 180 Fc binding
sites per particle were detected in the biomolecular corona
derived from 50% human serum by using a ﬂuorescence
reporter binder (quantum dots (QDs) functionalized with
antibodies). Subsequently, we developed a receptor fusion
protein expression system to study speciﬁc recognition by the
LDL receptor (LDLR) and Fc-gamma receptor I (FcγRI) in
appropriate biological milieu. We recognize the diﬃculty of
maintaining eﬀective receptor interactions with soluble receptor
fragments for most receptors of interest. Thus, the purpose of
these receptor fusion systems is to host relevant receptors, in a
manner that retains binding capacity, without seeking to re-
engineer the host cell, and all of the complexity and uncertainty
this entails. As such, the readout of a speciﬁc recognition of a
biomolecular corona by receptors is an increase of NP uptake
when cells express the receptors in comparison to being devoid
of the receptors. The presence of free proteins in normal serum
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is likely to decrease the detection window, as the competition
between free proteins and NP-adsorbed protein recognition
motifs for speciﬁc membrane receptors would only occur in
receptor-expressing cells. Therefore, NP uptake was carried out
in human serum that was depleted from the free proteins that
are binding ligands for a given receptor in this study. Our data
have shown that the uptake of NPs is signiﬁcantly increased in
the cells with greatly elevated expression of either LDLR or
FcγRI, suggesting that the speciﬁc recognition of the corona by
both receptors is coexistent. The speciﬁcity of the receptor
recognition was further conﬁrmed by competition binding of
free ligands with increasing concentrations. Taken together, this
study illustrates that the biomolecular corona of NPs retains
multiple binding motifs, which can be speciﬁcally recognized by
diﬀerent receptors potentially with diverse receptor−ligand
aﬃnity.
RESULTS AND DISCUSSION
Physiochemical Characterization of NPs in Biological
Milieu. For many particle−serum systems, the strongly bound
hard corona is suﬃciently stable so that it is possible to connect
the surface expression of surface-adsorbed protein epitopes to
the cell biological interactions.32 Thus, we ﬁrst expose 100 nm
SiO2 NPs to diﬀerent percentages of human serum (i.e., 10, 30,
and 50%) and isolate the hard corona−NP complexes by
centrifugation. Using denatured polyacrylamide gel electro-
phoresis (SDS-PAGE) and mass spectrometry, the irreversibly
bound hard corona proteins on SiO2 NPs were separated,
identiﬁed, and analyzed (Figure 1a,b and Table S1). Lip-
oproteins and immunoglobulins were found to be abundant in
all coronas with more than 10 and 20% of the total corona
proteins, respectively. Key examples include LDL and IgG.
LDL particles (20−30 nm in diameter), containing several
thousand cholesterol, phospholipid, and triglyceride molecules,
possess a single copy of ApoB-100, which interacts with the
Figure 1. Physicochemical characterization of serum corona on 100 nm SiO2 NPs. (a) SDS-PAGE of protein coronas recovered from SiO2
NPs following incubation with human serum at various concentrations. (b) Distribution of protein groups in human serum corona analyzed
by LC-MS/MS. The proteins on the SDS-PAGE were identiﬁed by LC-MS/MS after in-gel tryptic digestion. The abundance of protein groups
is expressed as protein mass percentage of the total corona proteins. (c) Diﬀerential centrifugal sedimentation analysis of NP dispersions in
delipidized human serum for various time periods: NPs with hard coronas formed in 10, 30, and 50% of human serum were redispersed in 10,
30, and 50% delipidized human serum for 1, 4, and 7 h, respectively.
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LDLR.33−35 IgG, the most abundant type of antibody in
circulatory system, consists of four peptide chains. Through the
Fc region, IgG binds to a family of Fc-gamma receptors
(including FcγRI) to mediate various immunological responses
(e.g., activation of phagocytes and antibody-dependent cell-
mediated cytotoxicity).36 It is unclear if the higher amount of
IgG is a consequence of nonspeciﬁc adsorption or secondary
recognition of disrupted corona proteins by blood-borne
antibodies.
Next, we sought to characterize their physicochemical
properties in appropriate biological milieu. In general, for
nanomaterials, the role of the milieu is critical and cell origin
must be matched to the appropriate biological ﬂuid to ensure
ﬁdelity of protein recognition.29 For the following studies, we
intend to use LDL as an example to illustrate the concept. First,
we redispersed the corona−NP complexes in serum depleted of
the lipoproteins (see lipoprotein depletion in Figure S1), as it is
important to examine the particle uptake in the absence of free
LDL to avoid competitive binding. Subsequently, we
characterized the same NP−corona dispersions that were
used for cell uptake studies with varied serum concentrations
and incubation times. Time-resolved diﬀerential centrifugal
sedimentation (DCS) analyses showed that in 10% delipidized
serum there is a degree of instability of the dispersion over
some hours, but for both 30 and 50% serum concentrations, the
dispersions are stable over the lifetime of typical cell uptake
experiments (Figure 1c).
For such stable well-deﬁned dispersions, we can analyze the
epitopes presented at the surface of nanoparticle−corona
complexes using immuno-labeling approaches that have the
sensitivity to detect 2−4 epitopes per nanoparticle.37
Monoclonal antibody (mAb) that recognizes the region of
AA 97−526 of ApoB-100, close to the LDLR recognition site,
was conjugated to a gold NP (4.5 nm, Figure S2a,b) or a QD (4
nm, Figure S2c,d). After incubation with immuno-gold NP−
mAbs, the ApoB-100 epitopes were visualized by transmission
electron microscopy (TEM) (Figure 2a,b). To quantitatively
detect the epitope presentation in the same conditions as the
NPs are exposed to the cells, we employed a QD−mAb
mapping technique.38 First, we examined the titration of ApoB-
100 epitopes on the coronas formed by exposure of NPs to 10,
30, and 50% human serum at 37 °C for 1 h and redispersed in
PBS. Diﬀerent numbers of ApoB-100 epitopes were detected
on the diﬀerent coronas, with the 10% serum corona showing
the highest number of ApoB-100 epitopes (Figure 2c).
Subsequently, we performed the titration curve of QD−mAb
probes with the corona−NP complexes that were formed in
50% serum and then redispersed in 50% delipidized serum for
1, 4, and 7 h. The three titration curves showed signiﬁcant
overlapping, suggesting that the number of epitopes remains
relatively constant throughout the time period (Figure 2d). It is
Figure 2. Epitope mapping of ApoB-100 on the serum corona of 100 nm SiO2 NPs. (a) Schematic representation of epitope mapping of
ApoB-100 on the protein corona of SiO2 NPs by 5 nm immuno-gold NPs conjugated with antibodies recognizing the ApoB-100 epitope. (b)
Electron micrographs of ApoB-100 epitopes on SiO2 NPs with a corona formed in 50% of human serum and subsequently incubated in 50% of
delipidized serum for 4 h. (c,d) Quantiﬁcation of ApoB-100 epitope on corona−NP complexes using immuno-QDs. (c) Corona−NP
complexes were formed in 10, 30, and 50% human serum and subsequently redispersed in PBS for 1 h. The immuno-QD labeling was
performed with the corona−NP dispersion in PBS. (d) Corona−NP complexes were formed in 50% human serum and subsequently
redispersed in 50% delipidized human serum and incubated for 1, 4, and 7 h. The immuno-QDs were obtained with the corona−NP
dispersion in 50% delipidized serum. Data represent the mean and standard deviation of three independent replicates.
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noted that the number of ApoB-100 epitopes reached a plateau
of 60 with an increased ratio of QD−mAb probes to SiO2 NPs
(Figure 2d), which is similar to the number of ApoB-100
epitopes quantiﬁed for the same hard corona (i.e., 50% serum
corona) redispersed in PBS for 1 h (Figure 2c). This further
supports the notion that the corona−NP complexes are stable.
Figure 2 establishes that the potential recognition fragment of
ApoB-100 is indeed extensively presented at the NP surface in
biological milieu. The question is if it is still recognizable by the
relevant receptor, LDLR.
Target Cells for Study of NP−Receptor Interactions. A
straightforward way of detecting speciﬁc uptake pathways is to
compare the NP uptake kinetics curves (for example, using
time-resolved ﬂow cytometry) of two identical populations of
cells, one of which has many less (or more) receptors of a given
type than the other population of cells with other key receptors
that can interact with the NPs remaining unchanged.39
Silencing RNA (siRNA) of the receptors of interest could be
used to determine recognition of NPs by decreasing the
receptor expression. To explore the siRNA approach, we
transfected LDLR siRNA to decrease the endogenous
expression of LDLR in A549 human lung epithelial cells
(Figure S3). By comparison of particle uptake between LDLR
siRNA and scrambled siRNA-transfected A549 cells, it is
conﬁrmed that LDLR down-regulation leads to a decrease of
NP uptake (Figure S4). It is worth noting that LDL exists in
diﬀerent forms in serum (e.g., oxidized LDL), and besides
LDLR, it can be recognized by other receptors, including LOX-
1, CD36, and Toll-like receptor 4 (TLR-4).40,41 A closer
analysis has shown that transfection with LDLR siRNA in A549
cells concurrently increased LOX-1 expression (Figure S3),
suggesting a high degree of co-regulation of the genes. Given
the cross-talking between the receptors, it suggests that
comparison of reference and silenced cells may not be a
reliable approach in this case.
Alternatively, in this study, we have developed a receptor-tag
fusion protein expression system that can “host” a range of
target receptors in HEK-293T cells (Figure 3). These cells have
Figure 3. Expression of human LDLR in HEK-293T cells. (a) Scheme of LDLR fused with a HaloTag protein at its N-terminus. The HaloTag
protein forms a covalent bond with a ﬂuorescent HaloTag ligand, TMR. (b) Expression of LDLR−HaloTag fusion protein in cells transfected
with a LDLR vector after incubation with TMR measured by ﬂow cytometry. (c) Expression of a HaloTag protein in cells transfected with an
empty vector after incubation with TMR measured by ﬂow cytometry. Cells were sorted to two populations (high and low) based on the TMR
intensity. (d) Western blot analysis of LDLR expression (MW 95 kDa) probed by using an anti-LDLR monoclonal antibody. (e)
Quantiﬁcation of LDLR mRNA level by RT-qPCR after transfection with a LDLR vector in the total cell population (LDLR-T), sorted high
TMR (LDLR-H) and low TMR (LDLR-L) subpopulations, as well as equivalent samples after transfection with an empty vector. The data are
shown as the mean ± standard deviation of triplicates. (f) Uptake kinetics of BODIPY-LDL (5 μg mL−1) by cells transfected with a LDLR
vector in 50% human serum analyzed by ﬂow cytometry. Data represent the median ﬂuorescence intensity of transfected cells (high TMR
subpopulation) performed in duplicates. At least 15 000 cells were analyzed in each repeat. (g) Example of a 2D plot of BODIPY-LDL and
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a very low endogenous expression level of LDLR, and
transfection of LDLR does not appear to co-regulate at the
gene (or protein) level within the relevant receptor clusters
(Figure S5). Crucially, the receptor is fused with the HaloTag,
which can then be labeled with a ﬂuorescent HaloTag ligand,
TMR (Figure 3a). This dye labeling serves as an intrinsic
measure of receptor expression on a cell-by-cell basis using ﬂow
cytometry. As it is shown in Figure 3b,c, the expression of the
LDLR−HaloTag fusion protein and HaloTag protein alone
varied signiﬁcantly between cells. Some cells failed to be
transfected (the left-most low TMR subpopulation in Figure
3b,c) even with optimization of the transfection (Figure S6).
Hence, we note that if the complete ensemble of cells after
transfection is used (both parts of the populations in Figure
3b), it becomes diﬃcult to identify NP−receptor recognition.
The correlation between receptor expression level and NP
uptake is critical for conﬁrming the speciﬁc corona epitope−
receptor recognition, given the heterogeneity in both receptor
expression and particle surface presentation. Thus, cell
subpopulations (i.e., high TMR and low TMR) were sorted
based on TMR intensity. Western blot (Figure 3d) and RT-
qPCR (Figure 3e) both conﬁrm that TMR levels can be used as
a proxy for receptor expression.
To conﬁrm functionality of the expressed LDLR, we
examined the uptake of ﬂuorescently labeled LDL in the high
TMR subpopulations (i.e., transfected cells). A 4-fold increase
in the ﬂuorescence of cells transfected with LDLR was observed
compared to that of the empty vector transfected cells (Figure
3f). It is noted that the LDL uptake was independent of LDLR
expression level in the high TMR subpopulation (Figure 3g),
suggesting that average numbers of expressed plasma
membrane receptors are high and functional.
In Situ Interactions of NPs with LDLR. Using the above-
mentioned LDLR-tag fusion protein expression system, we
examined the cell membrane adhesion and uptake of NP−
corona in delipidized serum. For the membrane adhesion
experiment, the cells were incubated with NP−corona
complexes at 4 °C for 1 and 4 h followed by extensive washes
to remove unbound NPs and subsequently chased in NP-free
media at 37 °C for 30 min. For the uptake experiment, the cells
were continuously incubated with NP−corona complexes at 37
°C for various time intervals. As shown in Figure 4, signiﬁcantly
increased membrane adhesion and uptake by LDLR-transfected
cells (i.e., the high TMR subpopulation) was observed in all
dispersions in comparison to cells transfected with an empty
vector. It is also noted that at higher NP concentration (1 mg
mL−1) and a higher serum concentration (50% delipidized
serum), the speciﬁc uptake of NPs by LDLR was maximized, as
the baseline uptake (i.e., uptake in cells transfected with empty
vector) was minimized due to other uptake pathways
suppressed by serum competition (Figure 4c,d). Under such
conditions, the scatter plot (4 h time point as an example)
showed a high correlation between LDLR expression and NP
uptake on a cell-by-cell basis in the transfected cells
(highlighted in the inset box of Figure 4e).
To further establish the speciﬁcity of the ApoB-100
interaction, we carried out competition uptake experiments
(50% delipidized serum, 4 h) for conditions identical to those
Figure 4. Membrane adhesion and uptake of human serum corona−SiO2 NP complexes in delipidized serum. (a,b) Membrane adhesion of
corona−NP complexes in delipidized serum. Cells were exposed to corona−NP complexes in 30% (a) and 50% (b) delipidized serum at 4 °C
for 1 and 4 h, followed incubation at 37 °C for 30 min. Data represent the median ﬂuorescence intensity of transfected cells (high TMR
subpopulation) performed in duplicates. At least 15 000 cells in each repeat were measured by ﬂow cytometry. (c,d) Uptake of corona−NP
complexes in delipidized serum. Cells were exposed to corona−NP complexes in 30% (c) and 50% (d) delipidized serum at 37 °C for 1, 4, and
7 h. Data represent the median ﬂuorescence intensity of transfected cells (high TMR subpopulation) performed in duplicates. At least 15 000
cells were analyzed in each repeat. (e) Example of a 2D plot of NP and TMR intensity (50% delipidized serum, 4 h incubation). High TMR
subpopulation is highlighted in the square. Blue: LDLR-transfected cells. Red: Empty vector transfected cells.
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in Figure 4c,d but in the presence of increasing concentrations
of ﬂuorescently labeled LDL (Figure 5). Then we can
simultaneously measure the uptake of NPs and LDL and ﬁnd
that at around 16 nM LDL there is quite a sharp accumulated
displacement-type transition in which predominantly NP
uptake crosses over to predominantly LDL uptake (Figure
5a−c). The scatter plot of LDL and NP ﬂuorescence intensity
indicates that cells that interact most strongly with LDL also
have the highest NP uptake, suggesting involvement of the
same receptor (Figure 5d). Confocal microscopy images have
also shown a progressive competitive uptake of NPs with an
increase of free LDL (Figure 5e−g).
We remark that the speciﬁc recognition of the serum corona
by LDLR can be reproduced from independent experiments
using the SiO2 NPs made in house and commercially sourced
with the same surface and similar size (Figure S7). Collectively
these observations set a high standard of reproducibility, which
we ﬁnd to be broadly applicable to a number of other particle
and receptor systems.
Concurrent Interactions of NPs with the FcγRI
Receptor. To provide a diﬀerent perspective, we present (in
less detail) analogous data for FcγRI, a receptor that recognizes
the Fc regions of IgGs, and a member of the important receptor
superfamily that promotes phagocytosis of (for example)
opsonized particles and infectious agents.42,43 The presentation
of Fc epitopes in the biomolecular corona was quantiﬁed using
anti-IgG (Fc) QD labeling. It was shown around 180 Fc
epitopes were detected in the corona (Figure 6b), which is
higher than the ApoB-100 epitopes (around 60 epitopes) and is
consistent with more abundant immunoglobulins found in the
corona than in apolipoproteins (Figure 1b).
Next, we employed the receptor-tag fusion expression system
to examine the speciﬁc recognition by the FcγRI receptor. As
shown in Figure 6d, FcγRI-transfected cells exhibited increased
Figure 5. Competitive uptake of human serum corona−SiO2 NP complexes by LDL in delipidized serum. Cells were incubated with corona−
NP complexes (labeled with FITC, 0.1 mg mL−1) and increasing concentrations of AF647-LDL (0 to 64 nM) in 50% delipidized serum at 37
°C for 4 h. NP (a) and LDL (b) uptake was measured by ﬂow cytometry. Data are the median ﬂuorescence intensity of transfected cells (high
TMR subpopulation) performed in duplicates. (c) Uptake of NPs competed with LDL in LDLR-transfected cells. Data are shown as the
median of cell ﬂuorescence intensity of transfected cells ± standard deviation of duplicates. (d) Two-dimensional scatter plots show uptake of
NPs and LDL in untreated cells, LDLR-transfected cells in the absence and presence of AF647-LDL. Confocal images of NP uptake (in green)
in LDLR-transfected cells (stained with TMR in red) (e) in the absence of LDL and in the presence of (f) 4 nM LDL and (g) 64 nM LDL.
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uptake of particles compared to that of untransfected cells in
both 30 and 50% IgG-depleted serum, suggesting that FcγRI
plays a role in particle recognition. The overall uptake scale in
IgG-depleted serum is much smaller than that in LDL-depleted
serum, despite the fact that abundance of IgG and LDL in the
corona and the aﬃnity of free IgG and LDL to FcγRI and
LDLR, respectively, are comparable. Also, uptake using dual
depleted serum (i.e., lipid- and IgG-depleted) shows little
diﬀerence between FcγRI-transfected and control cells (Figure
S8), possibly suggesting a much larger interaction between
particles and LDLR.44 The reasons for the apparently less
eﬀective interaction of IgG are not clear, and we do not believe
it prudent to overinterpret this observation. We do note,
however, that the typical aﬃnities of recognition sites on NPs
may be quite unrelated to that of the native protein and could
also vary signiﬁcantly on a particle-by-particle basis. Such
questions go far beyond the current studies and may require
additional tools.
CONCLUSIONS
Fundamentally, the size of NPs moves them into the range
where many intrinsic biological messages are passed and
processed. Since adsorption of biomolecules on the NPs
“labels” them with endogenous molecules, this potentially
allows for ubiquitous “accidental” involvement in biological
processing. Thus, NPs may be “mistaken” for endogenous (e.g.,
lipoproteins) or commonly occurring exogenous objects (e.g.,
viruses), potentially manifested in the nature of their clearance
and other outcomes. In this study, by using LDL and IgG as
examples, we have demonstrated that adsorbed proteins on
SiO2 NPs can present functional epitopes to allow the speciﬁc
recognition of receptors. While this study has been focused on
two types of receptors, we have been able to express a wide
spectrum of receptors using such a system (e.g., scavenger
receptor class A member 1, scavenger receptor class B member
1, stabilin-1, stabilin-2, and the other 10 receptors that are
abundant in the liver) and consider the platform will be of
broad signiﬁcance for NP−receptor recognition studies.
It would also be important to note that these are only the
ﬁrst steps. There are still several signiﬁcant limitations that are a
consequence of the complexity of NP−cell interactions. For
example, NP−protein complexes are highly heterogeneous
systems in which we have recognized major contributions from
predominant, not rare, NP subpopulations. In addition,
multivalent interactions between receptors and NPs have
often been speculated upon, but the synergies between
receptors at the interface of NPs are poorly studied, and such
eﬀects are yet to be understood. Still, we now have systematic
mapping and cellular tools that allow us to connect the real
nature of the bio−nano interface to cellular interactions. This
brings closer the microscopic connection between a particle
and its biological impact, with all the promise that could hold
for predicting and controlling biological outcomes.
METHODS
Materials. Fluorescein isothiocyanate (FITC)-labeled 100 nm SiO2
NPs with a plain surface were synthesized at the CBNI as described
previously.45 The 100 nm green ﬂuorescent, plain surface SiO2 NPs
(PSi-G0.1) were purchased from KISKER-BIOTECH (see character-
ization in Figure S9). Anti-LDL receptor antibody [1B10H10]
(ab204941), anti-FcγRI antibody [3D3] (ab140779), and anti-mouse
Figure 6. Epitope mapping of IgG (Fc) in the serum corona of SiO2 NPs and their cellular recognition by the FcγRI receptor in IgG-depleted
serum. (a) Schematic representation of epitope mapping of the Fc region on the corona of SiO2 NPs in IgG-depleted serum by immuno-QD
labeling. (b) Quantiﬁcation of the Fc epitope on corona−NP complexes using immuno-QDs. The corona−NP complexes were formed in 30
and 50% human serum and subsequently redispersed in PBS for 1 h. The immuno-QD labeling was measured with the corona−NP dispersion
in PBS using ﬂuorescence spectroscopy. (c,d) Uptake of corona−NP complexes in IgG-depleted serum. Cells were exposed to corona−NP
complexes in 30% (c) and 50% (d) IgG-depleted serum at 37 °C for 1, 4, and 7 h. Data represent the median ﬂuorescence intensity of
transfected cells (high TMR subpopulation) performed in duplicates. At least 15 000 cells were analyzed in each repeat.
ACS Nano Article
DOI: 10.1021/acsnano.6b07933
ACS Nano 2017, 11, 1884−1893
1890
IgG H+L (HRP) (ab6728) were purchased from Abcam. Anti-ApoB-
100 sc-13538, anti-ApoA-I sc-13549, and anti-ApoE sc-13521 were
purchased from Santacruz Biotech. BODIPY-LDL (L3483), CD64/
FCGR1A antibody (10.1) MA1-10270, goat anti-mouse IgG (H+L)
secondary antibody, and Alexa Fluor 488 conjugate (A11029) were
ordered from Thermo Fisher. Human serum was purchased from
BIOCHROM. Delipidized human serum was purchased from
SERALAB. IgG-depleted human serum was purchased from
INNOV-RESEARCH. The plasmid vectors for expression of LDLR
(FHC01394) and FcγRI (FHC03501) were purchased from KAZUSA
DNA Research Institute. Propan-2-ol (P/7507/5) was purchased from
Fisher Chemical. LDLR silencer select siRNA (s224006), silencer
select negative control no. 1 (439064), and oligofectamine transfection
reagent (12252011) were purchased from Thermo Fisher. Skimmed
milk powder (70166), sodium dodecyl sulfate (L3771), glycine
(G8898), ammonium persulfate (A3678), Trizma base (T1503),
Tween 20 (P1379), ethylenediaminetetraacetic acid disodium salt
dihydrate, EDTA (E4884), N,N,N′,N′-tetramethylethylenediamine
(T9281), select agar (A5054), acrylamide/bisacrylamide, 40% solution
(A7802), ampicillin (A9393), DL-dithiothreitol (D5545), ethanol
(32294-2), methanol (24229-2), 3-mercaptopropionic acid (M5801),
cadmium chloride (202908), hydrogen tetrachloroaurate(III)
(520918), 4-aminophenyl β-D-galactopyranoside (A9545), sodium
borohydride (S9125), N-(3-(dimethylamino)propyl)-N′-ethylcarbodii-
mide hydrochloride (E6383), N-hydroxysulfosuccinimide sodium salt
(56485), and methoxypolyethylene glycol amine (07964) were
purchased from Sigma-Aldrich and used as received. Color plus
prestained protein ladder, broad range (10−230 kDa) (P7711S) and
blue loading buﬀer for SDS-PAGE were purchased from New England
Bio-Laboratories (cat. no. B77035). PVC calibration standard for DCS
measurements 483 nm (PS000483) was ordered from Analytik Ltd.
BCA protein assay kit (23227) and RIPA buﬀer (89901) were ordered
from Thermo Scientiﬁc. Propan-2-ol (P/7507/5) was purchased from
Fisher Chemical. Tellurium, 99.8%, powder (315990250) was
purchased from Acros Organics.
NP Characterization. SiO2 NPs used in this study were
characterized by dynamic light scattering and DCS to ensure the
stability of the dispersion (Figure S9). To obtain the hard corona, 1
mg of 100 nm SiO2 NPs was incubated with 1 mL of 10% human
serum (5 mg mL−1 protein concentration), 30% human serum (15 mg
mL−1 protein concentration), or 50% human serum (25 mg mL−1
protein concentration) at 37 °C for 1 h on a shaker followed by
centrifugation at 16 000 rcf for 20 min. After centrifugation, the pellet
was redispersed and washed with phosphate-buﬀered saline (PBS, pH
7.4) three times. The protein corona was analyzed by SDS-PAGE and
LC-MS/MS following the protocol described previously.3 The
corona−NP complexes were redispersed in 10, 30, or 50% delipidized
human serum and were characterized by DCS at diﬀerent time points
before the epitope mapping analysis. The NP dispersions were
characterized by DCS using a CPS disc centrifuge DC24000. For SiO2
NPs, a 8−24% sucrose density gradient (suitable for the nanoparticle
density range used) prepared in relevant solvents (PBS, pH 7.4) was
used with a disk speed of 20 000 rpm. The particles were measured
between 0.001 and 1 μm, with each measurement being calibrated with
a PVC standard with a nominal size of 483 nm (Analytic Ltd.).
Epitope Mapping. The synthesis of small gold NPs (5 nm) was
performed following the procedure reported previously.46 In order to
functionalize the gold NPs with antibodies, the citrate of the NP
surface was exchanged by O-(2-carboxyethyl)-O′-(2-mercaptoethyl)-
heptaethylene glycol (SH-PEG (7)-COOH, MW = 458.56 g/mol).
Brieﬂy, 50 mL of gold NPs after synthesis was incubated overnight,
under continuous stirring, with SDS (0.03%), NaOH (25 mM), and an
equivalent amount of SH-PEG (7)-COOH to obtain 5000 chains per
NP. The carboxylated gold NPs were washed three times and
concentrated with centrifugal ﬁlter units (10 000 MWCO). The gold
NPs were characterized by DCS and EM. The synthesis of
mercaptopropionic acid (MPA)-protected CdTe QDs was performed
following the procedure reported by Penadeś et al.47 The QDs were
puriﬁed by precipitation with acetone. Finally, the QDs were separated
by centrifugation and dialyzed 48 h against PBS buﬀer. The QD
particles were characterized by DCS and ﬂuorescence spectroscopy.
The CdTe−MPA QDs and gold NPs were functionalized with
antibodies: 1 mL of NP suspension (3.3 nmol) was mixed with 0.4 mg
of EDC and 0.8 mg of sulfo-NHS in PBS buﬀer pH 7.4, and the
mixture was incubated at 37 °C for 30 min. The activated NP solution
was applied to a PD-10 column using 10 mM PBS pH 7.4 as the
exchange buﬀer. Then 0.6 nmol of IgG antibody was added to 1 nmol
of NPs, and the mixture was stirred at 37 °C for 1 h. Subsequently, the
activated carboxylic groups were blocked with 5 mg of 4-aminophenyl
β-D-galactopyranoside, and the mixture was incubated overnight in a
ﬁnal volume of 1.5 mL. NPs conjugated with antibodies (650 nM)
were stored at 4 °C.
For the immuno-gold labeling, mAb−gold NPs (5 nm) in excess
were added to a given number of corona−NP complexes. After the
incubation, the NPs were collected by centrifugation at 16 000 rcf and
washed with PBS and Milli-Q water ﬁve times each to remove
unbound mAb−gold NPs. Then the samples were prepared for TEM
as described previously.30 Three hundred SiO2 NPs were analyzed for
immuno-gold label counting by a FEI Tecnai G2 20 Twin TEM
operating at an acceleration voltage of 200 kV. For the QD−mAb
labeling, diﬀerent amounts of immuno-QDs in PBS (up to ﬁnal
concentration at 500 nM) were added to the NP−corona complexes
(ﬁnal concentration at 1 mg mL−1) under constant agitation for 1 h at
37 °C. Subsequently, the samples were centrifuged at 16 000 rcf and
redispersed in fresh PBS twice to remove the unbound QD−mAbs.
The interaction between the immuno-QDs and the corona was studied
using steady-state ﬂuorescence spectroscopy as described previously.31
Cell Culture. Human embryonic kidney (HEK-293T) cells (ATCC
CRL-3216) and human adenocarcinomic alveolar basal epithelial A549
cells (ATCC-CCL-185) were purchased from ATCC, which were
authenticated by the ATCC. HEK-293T cells were cultured in
DMEM, high glucose, Glutamax (GIBCO), supplemented with 10%
fetal bovine serum (FBS, GIBCO) in a humidiﬁed chamber at 37 °C
under 5% CO2. A549 cells were cultured in MEM (GIBCO),
supplemented with 10% FBS at 37 °C and 5% CO2. Cells were grown
in their preferred environment and passaged three times a week, as
they approached 70−80% surface coverage. The cells were routinely
tested for mycoplasma contamination by using the MycoAlert assay kit
(Cambrex Bio Science, Nottingham, UK).
RNA Extraction and RT-qPCR. RNA was extracted using an
InviTrapSpin cell RNA mini kit from Stratec (0711). The amount of
RNA was quantiﬁed by NanoDrop, and the cDNA was obtained by
reverse transcription. Quantitative PCR was performed with the cDNA
of each population of interest and the speciﬁc primers for each
receptor. Comparative CT method (ΔΔCT) was used to perform the
calculations. The CT (cycle treshold) of the receptor of interest was
normalized with the CT of the β-actin to obtain its ΔCT. The values
of ΔCT of the receptors were further normalized with the ΔCT of the
control cells (i.e., untransfected cells), the result of which generated the
ﬁnal data set (ΔΔCT).
Western Blot. Proteins separated by SDS-PAGE were transferred
to a PVDF membrane using a mini-PROTEAN tetra trans-blot
module under a constant voltage of 100 V for 1 h. Membranes were
then incubated at room temperature for 1 h in blocking solution of 5%
skimmed milk in TBS-TWEEN (150 mM NaCl, 10 mM Tris-HCl,
0.1% Tween, pH 7.5). Afterward, the membrane was incubated
overnight at 4 °C with the antibodies of interest in blocking solution
and washed for 1 h in TBS-TWEEN. The blot was incubated at room
temperature for 1 h with 1:2000 of anti-goat HRP in blocking solution
and washed for 1 h in TBS-TWEEN. The membrane was incubated
for 1 min in an ECL Western blotting substrate mix and visualized in a
Syngene G: BOX imaging system.
Silencing of LDLR Expression in A549 Cells. Seventeen
thousand cells were seeded in 24-well plates (Greiner) and incubated
for 24 h before silencing of LDLR. Cells were then transfected with
LDLR siRNA or scrambled siRNA using oligofectamine reagent
according to the manufacturer’s instructions and incubated for 72 h.
Transfection of HEK-293T Cells. HEK-293T cells were plated 24
h before transfection at a density of 104 000 cells in each well into a
ACS Nano Article
DOI: 10.1021/acsnano.6b07933
ACS Nano 2017, 11, 1884−1893
1891
12-well plate (Cellstar Greiner bio-one) in 1 mL of complete DMEM
Glutamax (GIBCO) medium supplemented with 10% FBS. After 24 h,
cells were transfected using a FuGENE 6 (Promega)-to-DNA ratio of
3.5:1 for LDLR and 3:1 for FcγRI. Plasmid DNA (0.02 μg μL−1) was
added to a sterile tube containing opti-MEM medium (GIBCO).
FuGENE 6 reagent was added to the solution and mixed carefully by
pipetting 15 times. The solution was incubated at room temperature
for 10 min. Next, 50 μL was then gently added dropwise onto each
well and incubated for 24 h at 37 °C and 5% CO2.
Cellular Uptake of NPs. To expose the cells to the NPs, after 24 h
of the transfection, cells were washed for at least 30 min in serum-free
DMEM. The medium was then replaced with the freshly prepared NP
dispersions. Experiments were performed by exposing the cells to the
NP dispersions at 0.1 or 1 mg mL−1 at 37 °C and 5% CO2 for 1, 4, and
7 h. Cells then were washed with 1 mL per well of completed DMEM
Glutamax supplemented with 10% FBS. One-ﬁfth of the volume was
replaced with TMR HaloTag ligand at a concentration of 200 nM in
completed DMEM Glutamax and incubated at 37 °C, 5% CO2 for 15
min. The cells were washed with completed DMEM Glutamax once
and PBS twice and harvested after trypsinization. Cell pellets were
redispersed in completed DMEM Glutamax and placed on ice. Cell
ﬂuorescence intensity was measured using a CyAn ADP (Beckman
Coulter ﬂow cytometer). Results are reported as the median of cell
ﬂuorescence intensity of transfected cells (high TMR subpopulation).
At least 15 000 cells were analyzed in each sample.
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(33) Kumar, V.; Butcher, S. J.; Öörni, K.; Engelhardt, P.; Heikkonen,
J.; Kaski, K.; Ala-Korpela, M.; Kovanen, P. T. Three-Dimensional
CryoEM Reconstruction of Native LDL Particles to 16Å Resolution at
Physiological Body Temperature. PLoS One 2011, 6, e18841.
(34) Mora, S.; Szklo, M.; Otvos, J. D.; Greenland, P.; Psaty, B. M.;
Goff, D. C., Jr.; O’Leary, D. H.; Saad, M. F.; Tsai, M. Y.; Sharrett, A. R.
LDL Particle Subclasses, LDL Particle Size, and Carotid Athero-
sclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA).
Atherosclerosis 2007, 192, 211−217.
(35) Segrest, J. P.; Jones, M. K.; De Loof, H.; Dashti, N. Structure of
Apolipoprotein B-100 in Low Density Lipoproteins. J. Lipid Res. 2001,
42, 1346−1367.
(36) Hansel, T. T.; Kropshofer, H.; Singer, T.; Mitchell, J. A.;
George, A. J. T. The Safety and Side Effects of Monoclonal Antibodies.
Nat. Rev. Drug Discovery 2010, 9, 325−338.
(37) Herda, L. M.; Hristov, D. R.; Lo Giudice, M. C.; Polo, E.;
Dawson, K. A. Mapping of Molecular Structure of the Nanoscale
Surface in Bionanoparticles. J. Am. Chem. Soc. 2017, 139, 111−114.
(38) Resch-Genger, U.; Grabolle, M.; Cavaliere-Jaricot, S.; Nitschke,
R.; Nann, T. Quantum Dots Versus Organic Dyes as Fluorescent
Labels. Nat. Methods 2008, 5, 763−775.
(39) Zarschler, K.; Prapainop, K.; Mahon, E.; Rocks, L.; Bramini, M.;
Kelly, P. M.; Stephan, H.; Dawson, K. A. Diagnostic Nanoparticle
Targeting of the EGF-Receptor in Complex Biological Conditions
Using Single-Domain Antibodies. Nanoscale 2014, 6, 6046−6056.
(40) Levitan, I.; Volkov, S.; Subbaiah, P. V. Oxidized LDL: Diversity,
Patterns of Recognition, and Pathophysiology. Antioxid. Redox
Signaling 2010, 13, 39−75.
(41) Brown, M. S.; Goldstein, J. L. Reversible Accumulation of
Cholesteryl Esters in Macrophages Incubated with Acetylated
Lipoproteins. J. Cell Biol. 1979, 82, 597−613.
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Preparation, Cytotoxicity, and Tumor Cell Death by Targeting
Transferrin Receptor. Part. Part. Syst. Charact. 2014, 31, 126−133.
ACS Nano Article
DOI: 10.1021/acsnano.6b07933
ACS Nano 2017, 11, 1884−1893
1893
